stockrow
Saturday 7 November 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
- EPS
- +3.06%
- Free cash flow
- −32.9%
Quarter to June 2026, against a year earlier
2.16
0.14
+6.93%
Follow ATOS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | 119 | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) | (38) | +20.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) | (38) | +20.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (388.97) | (164.55) | (82.46) | (30.43) | (29.53) | (2.70) | (3.15) | (3.60) | (3.00) | (4.04) | (4.38) | (39.8%) | ||||||
| Cash flow | (327.72) | (101.45) | (32.32) | (16.11) | (15.34) | (2.11) | (2.46) | (2.49) | (2.51) | (3.46) | (4.01) | (39.7%) | ||||||
| Capex | (0.56) | 0.00 | (0.40) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (44.7%) | ||||||
| Free cash flow | (328.28) | (101.45) | (32.72) | (16.12) | (15.35) | (2.11) | (2.46) | (2.49) | (2.51) | (3.46) | (4.01) | (39.7%) | ||||||
| Book value | 188.85 | 106.75 | 31.75 | 23.22 | 36.02 | 17.71 | 13.97 | 10.82 | 8.52 | 4.57 | 3.01 | (33.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 1 | 1 | 8 | 8 | 8 | 8 | 9 | 9 | +100.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (7) | (9) | (9) | (12) | (16) | (21) | (21) | (21) | (30) | (36) | +20.9% | |||||
| Capex | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +10.7% | ||||||
| Free cash flow | (5) | (7) | (9) | (9) | (12) | (16) | (21) | (21) | (21) | (30) | (36) | +20.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 2 | 7 | 9 | 13 | 27 | 138 | 113 | 87 | 69 | 37 | 26 | +36.9% | |||||
| Net debt | (3) | (7) | (10) | (13) | (40) | (136) | (111) | (89) | (71) | (41) | (26) | +33.5% | ||||||
| Shareholders’ equity | 3 | 7 | 9 | 13 | 27 | 138 | 118 | 91 | 71 | 39 | 27 | +32.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (122.62) | (173.71) | (230.17) | (131.55) | (77.90) | (22.39) | (20.36) | (27.39) | (29.54) | (56.06) | (77.91) | +66.6 pt | |||||
| ROIC | (35,321.81) | 0.00 | 0.00 | (2,321.12) | 0.00 | (777.78) | (248.52) | (801.74) | (6,100.04) | 0.00 | (3,918.83) | +35,321.8 pt | ||||||
| ROE | (186.26) | (213.05) | (342.46) | (182.33) | (114.42) | (25.11) | (21.10) | (28.80) | (31.39) | (62.74) | (89.23) | +123.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 6 | 7 | 6 | 6 | 8 | 8 | 11 | 10 | 13 | 14 | — | +9.9% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2015 · latest quarter Dec 2014 · fundamentals updated 26 Oct 2026
Atossa Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| CRVO CervoMed Inc. | $21.9M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $21.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MCRB Seres Therapeutics, Inc. | $20.8M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −576.66% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| ATOS Atossa Therapeutics, Inc. | $20.2M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | |
| IMMP Prima BioMed Ltd | $19.8M | — | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| BSEM BioStem Technologies, Inc. | $19.4M | — (loss-making) | — (loss-making) | −27.95% (below 0%: shrinking) | n/m | — | 61.28% | (106.35%) | Compare |
| COCP Cocrystal Pharma, Inc. | $19.3M | — (loss-making) | — (loss-making) | −81.05% (below 0%: shrinking) | n/m | −16.75% (below 0%: shrinking) | 100.00% | (3,032.38%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $18.5M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $20.3M | — | — | −13.97% | — | −45.33% | 80.64% | (104.12%) |
Pay and ownership Proxy statement filed 30 March 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.50m | 2.20m | (12.00) |
| 2024 | 2.76m | 3.02m | 79.00 |
| 2023 | 2.36m | 2.65m | (67.00) |
Ownership
Directors and executive officers, together
9.80%
Steven C. Quay, M.D., Ph.D.
8.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement